However, a study that used CRISPR to separately engineer different POLE and POLD1 mutations into two different mouse tumor cell lines found that ICI sensitivity was significantly improved in those syngeneic POLE and POLD1 tumors (107). This evidence concerns the gene POLE and neoplasm.